PMID- 34633743
OWN - NLM
STAT- MEDLINE
DCOM- 20220418
LR  - 20220418
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 130
IP  - 2
DP  - 2022 Feb
TI  - Mitosis-Karyorrhexis Index evaluation by digital image visual analysis for 
      application of International Neuroblastoma Pathology Classification in FNA 
      biopsy.
PG  - 128-135
LID - 10.1002/cncy.22520 [doi]
AB  - BACKGROUND: The Mitosis-Karyorrhexis Index (MKI) score is important in 
      neuroblastoma evaluation and in the application of the International 
      Neuroblastoma Pathology Classification (INPC). Currently, it is not standardized 
      for smears. Hence, the aim of this study was to devise and validate methods for 
      MKI evaluation in fine-needle aspiration biopsy (FNAB) of neuroblastoma. METHODS: 
      A total of 50 cases of neuroblastoma diagnosed by FNAB from January 2017 to 
      December 2019 were retrieved, and detailed cytomorphological evaluations were 
      performed. The MKI was evaluated, and the eyeball visual assessment score (EVAS) 
      was compared with the digital image visual analysis score (DIVAS) on cytology 
      smears and corresponding histology sections of cell blocks. The interobserver 
      reproducibility and concordance were calculated. INPC subtyping into favorable 
      and unfavorable groups was performed by the collation of age, MKI, and 
      cytomorphology and was correlated to clinical outcomes. RESULTS: Neuroblastoma 
      was categorized as undifferentiated (22 of 50) or poorly differentiated (28 of 
      50) on cytomorphology. The overall concordance for the MKI by 3 observers was 86% 
      (kappa = 0.85), and this increased to 98% in the high MKI category. MKI evaluations 
      on smears showed 96% concordance with cell block histology, and the EVAS was 
      concordant with the DIVAS in 86% of the cases. Overall, the MKI was high in 39 
      cases, intermediate in 4 cases, and low in 7 cases. The INPC category was 
      unfavorable in 90% (n = 45) and favorable in 10% (n = 5) and had significant 
      correlations with outcomes (P = .029). CONCLUSIONS: An MKI assessment on smears 
      by digital image visual analysis is accurate, reproducible, and objective and 
      should be incorporated into the routine reporting of neuroblastoma FNAB for 
      diagnostic schemas as per the INPC.
CI  - (c) 2021 American Cancer Society.
FAU - Bhardwaj, Neha
AU  - Bhardwaj N
AD  - Department of Cytology and Gynecological Pathology, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
FAU - Rohilla, Manish
AU  - Rohilla M
AUID- ORCID: 0000-0002-3551-2060
AD  - Department of Cytology and Gynecological Pathology, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
FAU - Trehan, Amita
AU  - Trehan A
AD  - Hematology-Oncology Division, Department of Pediatrics, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
FAU - Bansal, Deepak
AU  - Bansal D
AD  - Hematology-Oncology Division, Department of Pediatrics, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
FAU - Kakkar, Nandita
AU  - Kakkar N
AD  - Department of Histopathology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Srinivasan, Radhika
AU  - Srinivasan R
AUID- ORCID: 0000-0002-1771-091X
AD  - Department of Cytology and Gynecological Pathology, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20211011
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
SB  - IM
MH  - Biopsy, Fine-Needle
MH  - Humans
MH  - Infant
MH  - Mitosis
MH  - *Neuroblastoma/diagnosis/pathology
MH  - Prognosis
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - International Neuroblastoma Pathology Classification
OT  - Mitosis-Karyorrhexis Index
OT  - digital image visual analysis
OT  - fine-needle aspiration biopsy (FNAB)
OT  - neuroblastoma
EDAT- 2021/10/12 06:00
MHDA- 2022/04/19 06:00
CRDT- 2021/10/11 12:40
PHST- 2021/08/26 00:00 [revised]
PHST- 2021/06/28 00:00 [received]
PHST- 2021/09/15 00:00 [accepted]
PHST- 2021/10/12 06:00 [pubmed]
PHST- 2022/04/19 06:00 [medline]
PHST- 2021/10/11 12:40 [entrez]
AID - 10.1002/cncy.22520 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2022 Feb;130(2):128-135. doi: 10.1002/cncy.22520. Epub 2021 
      Oct 11.